Dapsone

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Dapsone

---

CLASS

Sulfone

---

MECHANISM OF ACTION

Bactericidal activity (An imidazopyridine amide drug that targets the mycobacterial cytochrome bcc-aa3 terminal oxidase)

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Experimental

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/12044304/

https://pubmed.ncbi.nlm.nih.gov/32091697/

---

SIMILAR TARGETS IN OTHER SPECIES

Inactive dihydropteroate synthase 2 ~ Mycobacterium leprae (strain TN)

---

DRUG BANK ID

DB00250

---

EXTERNAL LINKS

Human Metabolome Database HMDB0014395

KEGG Drug D00592

KEGG Compound C07666

PubChem Compound 2955

PubChem Substance 46505300

ChemSpider 2849

BindingDB 50029764

RxNav 3108


ChEBI 4325


ChEMBL CHEMBL1043

ZINC ZINC000000006310

Drugs.com
Drugs.com Drug Page  https://www.drugs.com/cdi/dapsone.html

Wikipedia Dapsone

---

REFERENCE

Espey K., D., Djomand, G., Diomande, I., Dosso, M., Saki Z., M., Kanga, J.-M., Spiegel A., R., Marston J., B., Gorelkin, L., Meyers M., W., Portaels, F., Deming S., M., & Horsburgh Jr, C. R. (2002). A pilot study of treatment of Buruli ulcer with rifampin and dapsone. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 6(1), 60?65. https://doi.org/10.1016/S1201-9712(02)90138-4



Pluschke, G., & R?ltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4

---